These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15546720)

  • 1. CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.
    Elzein E; Ibrahim P; Koltun DO; Rehder K; Shenk KD; Marquart TA; Jiang B; Li X; Natero R; Li Y; Nguyen M; Kerwar S; Chu N; Soohoo D; Hao J; Maydanik VY; Lustig DA; Zeng D; Leung K; Zablocki JA
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6017-21. PubMed ID: 15546720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitors of fatty acid oxidation as potential metabolic modulators.
    Elzein E; Shenk K; Ibrahim P; Marquart T; Kerwar S; Meyer S; Ahmed H; Zeng D; Chu N; Soohoo D; Wong S; Leung K; Zablocki J
    Bioorg Med Chem Lett; 2004 Feb; 14(4):973-7. PubMed ID: 15013004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
    Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
    J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic effects of thia fatty acids in rat liver depend on the position of the sulfur atom.
    Gudbrandsen OA; Dyrøy E; Bohov P; Skorve J; Berge RK
    Chem Biol Interact; 2005 Jun; 155(1-2):71-81. PubMed ID: 15949791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concerted action of leptin in regulation of fatty acid oxidation in skeletal muscle and liver.
    Wein S; Ukropec J; Gasperíková D; Klimes I; Seböková E
    Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):244-51. PubMed ID: 17479441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
    Cheng JF; Chen M; Wallace D; Tith S; Haramura M; Liu B; Mak CC; Arrhenius T; Reily S; Brown S; Thorn V; Harmon C; Barr R; Dyck JR; Lopaschuk GD; Nadzan AM
    J Med Chem; 2006 Mar; 49(5):1517-25. PubMed ID: 16509570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart.
    Wu L; Belardinelli L; Fraser H
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):372-9. PubMed ID: 18427280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
    DiMauro EF; Buchanan JL; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Janosky B; Lee JH; Li X; Martin MW; Tomlinson SA; White RD; Zheng XM; Patel VF; Fremeau RT
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4267-74. PubMed ID: 18640038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor.
    Mittapalli GK; Zhao F; Jackson A; Gao H; Lee H; Chow S; Kaur MP; Nguyen N; Zamboni R; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4955-61. PubMed ID: 22784640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents.
    Cheng JF; Huang Y; Penuliar R; Nishimoto M; Liu L; Arrhenius T; Yang G; O'leary E; Barbosa M; Barr R; Dyck JR; Lopaschuk GD; Nadzan AM
    J Med Chem; 2006 Jul; 49(14):4055-8. PubMed ID: 16821767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification.
    Bruce CR; Brolin C; Turner N; Cleasby ME; van der Leij FR; Cooney GJ; Kraegen EW
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1231-7. PubMed ID: 17179390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative inhibition studies of enoyl-CoA hydratase 1 and enoyl-CoA hydratase 2 in long-chain fatty acid oxidation.
    Wu L; Lin S; Li D
    Org Lett; 2008 Aug; 10(15):3355-8. PubMed ID: 18611036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.
    Turner N; Bruce CR; Beale SM; Hoehn KL; So T; Rolph MS; Cooney GJ
    Diabetes; 2007 Aug; 56(8):2085-92. PubMed ID: 17519422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
    Chiba J; Iimura S; Yoneda Y; Watanabe T; Muro F; Tsubokawa M; Iigou Y; Satoh A; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2007 Feb; 15(4):1679-93. PubMed ID: 17194595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.
    Feng DD; Biftu T; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Miller RR; Stearns RA; Strader CD; Tota L; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Jul; 10(13):1427-9. PubMed ID: 10888324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3.
    Li Z; Chen W; Hale JJ; Lynch CL; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Chrebet G; Parent SA; Bergstrom J; Card D; Forrest M; Quackenbush EJ; Wickham LA; Vargas H; Evans RM; Rosen H; Mandala S
    J Med Chem; 2005 Oct; 48(20):6169-73. PubMed ID: 16190743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation.
    Bentebibel A; Sebastián D; Herrero L; López-Viñas E; Serra D; Asins G; Gómez-Puertas P; Hegardt FG
    Biochemistry; 2006 Apr; 45(14):4339-50. PubMed ID: 16584169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.